The risk of diabetes mellitus in children born small for gestational age and treated with recombinant growth hormone

Elena Bozzola, S. Lauriola, M. F. Messina, G. Bona, M. Wasniewska, M. Bozzola, L. Tatò

Research output: Contribution to journalArticle

Abstract

Children born small for gestational age (SGA) are known to be at risk for both short stature and type 2 diabetes mellitus in later life. To evaluate the influence of recombinant growth hormone (rhGH) therapy on insulin sensitivity, 24 children born SGA were treated with GH at traditional doses, from 0.23 mg/kg/week (group A) to 0.46 mg/kg/week (group B). We evaluated glycosylated haemoglobin, basal glucose and insulin levels before and 1 and 2 years after GH therapy. The homeostasis model assessment (HOMA) index was used to evaluate insulin sensitivity. After 2 years of GH therapy, glycosylated haemoglobin and basal glucose did not change significantly. Insulin sensitivity fell, but still remained within the normal range. In conclusion, 2-year GH therapy had beneficial effects in SGA children without changes in glucose homeostasis. Moreover, the insulin sensitivity reduction did not correlate to the GH dose used.

Original languageEnglish
Pages (from-to)63-67
Number of pages5
JournalJournal of Pediatric Endocrinology and Metabolism
Volume18
Issue number1
Publication statusPublished - Jan 2005

Keywords

  • Children born small for gestational age
  • Diabetes mellitus
  • Growth hormone therapy
  • Insulin
  • Short stature

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'The risk of diabetes mellitus in children born small for gestational age and treated with recombinant growth hormone'. Together they form a unique fingerprint.

  • Cite this